Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial

Zahra Darabi, Mina Darand, Zahra Yari, Mehdie Hedayati, Amirhosein Faghihi, Shahram Agah and Azita Hekmatdoost*

Abstract

Objectives: The aim of this study was to investigate the effects of citrulline (Cit) supplementation on inflammatory markers and liver histopathology in patients with non-alcoholic fatty liver disease (NAFLD). In this clinical trial, fifty NAFLD patients were assigned to receive 2 g/day Cit or placebo for 3 months.

Results: At the end of study, serum high sensitive C-reactive protein (hs-CRP) and activity of nuclear factor kappa B (NF-κB) were reduced in Cit group significantly more than placebo group (P-value = 0.02 and < 0.01 respectively). Serum concentrations of tumor necrosis factor-α (TNF-α) was reduced in Cit group significantly more than placebo after adjusting for levels of baseline (P-value < 0.001). Moreover, Cit supplementation decreased serum alanine aminotransferase (ALT) and hepatic steatosis significantly (P = 0.04). Anthropometric measurements and hepatic enzymes did not change significantly in any group (P ≥ 0.05). In conclusion, our results showed that 12 weeks supplementation with 2 g/day Cit improved inflammatory markers in patients with NAFLD. Further studies with longer period of supplementation and different dosages of Cit are needed to be able to conclude.

Trial registration IRCT201703194010N18 on 2017-10-13

Keywords: Citrulline, NAFLD, Fatty liver, Inflammation, NASH

Introduction

Non-alcoholic fatty liver disease (NAFLD) begins from simple steatosis, and if it is not treated it may progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular [1–3]. Inflammation and lobular ballooning result from insistent hepatic injury then they can cause nonalcoholic steatohepatitis (NASH) and lastly may lead to cirrhosis [1]. NAFLD and NASH are reversible, while cirrhosis exhibit an irreversible stage of the disease [4]. The only proven treatment for NAFLD is lifestyle modification [2, 5], which can be more effective when combined with some dietary supplements [6–10].

Specific amino acids such as Citrulline (Cit) supplementation are suggested as effective strategies in amelioration of hepatic steatosis and insulin resistance (IR) in experimental models of NAFLD. They could improve hepatic steatosis through their effects on glucose tolerance, IR and lipid metabolism [11–14]. Some studies have shown potential effects of Cit on reducing inflammatory markers such as tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) [12, 15, 16], which can prevent development of disease to severe conditions such as NASH and cirrhosis [17]. The aim of current study was to investigate effects of Cit supplementation on liver enzymes,
inflammatory indices, hepatic elasticity, and echogenicity in patients with NAFLD.

**Main text**

**Materials and methods**

**Ethical consideration**

The study protocol was approved by the National Nutrition and Food Technology Research Institute of Sha-hid Beheshti University of Medical Science (IR.SBMU.nnftri.13950106). The trial was registered at Iranian registry of clinical trials (IRCT201703194010N18).

**Study design and participants**

The study was designed as a prospective randomized, Double-Blind, placebo-controlled, clinical trial. Patients with NAFLD were recruited from a private Hepatology clinic. NAFLD was diagnosed by a gastroenterologist according to Fibroscan results. Inclusion criteria included age older than 18 year and controlled attenuation parameter (CAP) score more than 260 in Fibroscan. Exclusion criteria included pregnancy and lactation in women, viral hepatitis, intake of alcohol, insulin injections and consuming hepatotoxic medications.

After explanation of study protocol, patients who agreed to participate in the study were randomly assigned to receive four capsules/day of either placebo (maltodextrin) or Cit (0.5 g) for 12 weeks. Cit capsules were filled by 500 mg L-citrulline Maleate, provided by Mardin Company, Tehran, Iran. Capsules containing Cit or placebo were identical in shape, size and color. Capsules containing Cit or placebo were placed in boxes, and labeled as A or B by a third person so that investigators and patients were blinded on group assignments. Both groups have been advised on an energy-balanced diet according to Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults from the National Institutes of Health and the North American Association [18]. Follow-up assessments have been implemented every 4 weeks after start of intervention. Compliance was evaluated through capsule count in each visit.

**Clinical and paraclinical assessments**

Weight, height, and waist circumferences of all participants were measured. BMI was calculated using the following formula: BMI = weight (kg)/height² (m). Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by photometric assay (Parsazmoun). Levels of gamma glutamine transferase (GGT) was measured by enzymatic colorimetric assay (Parsazmoun). Concentrations of fasting TNF-α (TNF-α; BOSTER, Pleasanton, CA, USA) and high-sensitivity C_reactive protein (hs-CRP) were measured by using an enzyme-linked immunosorbent assay (Bionik). Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) p65 was assessed in peripheral blood mononuclear cell (PBMC) nuclear extracts using ELISA kits (Cell Signaling) according to the manufacturer’s protocol. Hepatic steatosis and fibrosis were measured using FibroScan, and Ultrasound exam, which weredone at the beginning and end of the intervention by a hepatologist and a radiologist respectively. Assessment of physical activity was done at baseline and end of intervention by employing the metabolic equivalent of task (MET) questionnaire [19].

**Dietary assessment**

Three 24-h recalls for 2 weekdays and 1 weekend day were asked from participants at the beginning and end of study. Interviews were done by an expert dietitian. Nutrient intakes were assessed using Nutritionist 4 (First Data Bank) [20].

**Statistical analysis**

Data analyzed using SPSS21 software. Continuous and categorical data were presented as mean values with their standard deviations and frequency. Analyze of demographic variable were performed using t test or χ², as appropriate. Normal distribution of data was evaluated using the Kolmogorov–Smirnov. Paired t test and student t test were used to compare variables within and between groups respectively. In order to exclude the effects of confounding factors, the analysis of covariance test was used. All ANCOVA models were adjusted for the baseline value of each variable and mean changes in BMI, MET and energy.

The sample size was calculated for the Fibroscan controlled attenuation parameter (CAP) score. Determining sample size for this study was based on detection of a 10 unit difference in the mean CAP score with a power of 80% (β = 20%), yielding a sample size of 21 for each group. Due to the potential loss of samples, 25 patients in each group were considered [9].

**Results**

Fifty patients who met the study inclusion criteria were enrolled in this study. The flow chart of study enrollment is shown in Fig. 1. Eighty-three percent of patients completed 12 weeks of study protocol. Only three (12%) patient in the Cit group and three (12%) patient in the placebo group discontinued the study for personal reasons. The demographic, inflammatory and biochemical characteristics and liver histological parameters of two groups were similar at the baseline, only levels of TNF-α was significantly higher in placebo group at baseline.
There were no significant differences in waist circumference, BMI and weight between and within groups. Serum ALT was significantly reduced in Cit group after 12 weeks intervention period, while serum AST and GGT did not change significantly in any group. NF-κb activity and hs-CRP reduced significantly in the Cit group compared with the baseline and the placebo group (Table 1). After adjusting for levels of baseline, TNF-α was reduced in Cit group significantly more than placebo group (P = 0.049).

At the end of the study, results of Fibroscan showed a significant reduction of Hepatic steatosis and fibrosis in the Cit group; however, this reduction was not significantly different between groups (P > 0.05). According to Ultrasound exam, hepatic steatosis grade reduced in Cit group significantly more than placebo group (Table 2).

Discussion
To our knowledge, this study is the first randomized, clinical trial that evaluated the effect of Cit supplementation on markers of inflammation in patient with NAFLD. Results of this study have shown that consumption of 2 g/day Cit reduced markers of inflammation significantly.

The results of previous experimental studies are consistent with our results. Experimental studies have shown that Cit supplementation can reduce gene expression of Toll-like receptor 4 (TLR4), which results in inhibition of NF-kB activation and TNF-α production [11, 15, 16].

Another suggested mechanism for anti-inflammatory effects of Cit is its properties in reduction of oxidative stress. Cai et al. reported that Cit supplementation increased superoxide dismutase (SOD) activities and reduced levels of malondialdehyde (MDA) [21]. SOD can reduce extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) signaling activation. ERK1/2 inhibition leads to prevention of NF-kB activation and TNF-α production [22].

Moreover, Sellmann et al. showed that Cit supplementation protects animals fed a high fructose diet against hepatic lipid peroxidation. Increased lipid peroxidation is the main cause of redox sensitive nuclear factor κB activity and consequently production of TNF-α [23, 24].

Table 1 Inflammatory biomarkers of patients at baseline and after 3 month

| Characteristics               | Baseline Mean ± SD | After 3 month Mean ± SD | P*  | Change Mean ± SD | P†  |
|-------------------------------|--------------------|-------------------------|-----|------------------|-----|
| hs-CRP (ng/ml)                |                    |                         |     |                  |     |
| Cit                           | 5696 ± 2862        | 3901 ± 2760             | <0.01 | -1794 ± 2025    | 0.02|
| Placebo                       | 6323 ± 4812        | 6143 ± 4851             | 0.713 | -1806 ± 1866    |     |
| TNF-α (pg/ml)                 |                    |                         |     |                  |     |
| Cit                           | 15.1 ± 4.74        | 14.6 ± 2.01             | 0.66| -0.55 ± 0.07    | 0.57|
| Placebo                       | 18.5 ± 2.04        | 17.4 ± 1.57             | 0.05| -1.29 ± 2.37    |     |
| NF-κb (ng/mg protein)         |                    |                         |     |                  |     |
| Cit                           | 2.46 ± 0.72        | 2.11 ± 0.42             | 0.02| -0.30 ± 0.63    | <0.001|
| Placebo                       | 1.99 ± 1.34        | 2.64 ± 0.72             | 0.09| 0.64 ± 1.29     |     |

TNF-α tumor necrosis factor α, hs-CRP C reactive protein, NF-κb nuclear factor kappa B cells

* P values indicate comparison within groups
† P values indicate comparison between the changes of each variable between two groups
Table 2 Liver steatosis and fibrosis of patients at baseline and after 3 month (Mean values and standard deviations)

| Characteristics          | Baseline Mean ± SD | After 3 month Mean ± SD | P* | Change Mean ± SD | P† |
|--------------------------|--------------------|-------------------------|----|------------------|----|
| Fibrosis (kPa)           |                    |                         |    |                  |    |
| Cit                      | 5.85±1.71          | 5.84±2.00               | 0.44| −0.21±1.18       | 0.8|
| Placebo                  | 6.27±2.08          | 6.12±1.81               | 0.15| −0.43±1.15       |    |
| Steatosis grade (0/1/2/3) |                    |                         |    |                  |    |
| Cit                      | 2.86±0.35          | 2.44±0.85               | 0.04| −0.44±0.85       | 0.8|
| Placebo                  | 2.62±0.66          | 2.38±0.88               | 0.13| −0.37±0.95       |    |
| Steatosis (dB/m)         |                    |                         |    |                  |    |
| Cit                      | 320.8±29.6         | 304.5±39.1              | 0.127| −16.33±43.18    | 0.97|
| Placebo                  | 315.5±36.8         | 299.6±45.7              | 0.171| −15.87±44.19    |    |

* P values indicate comparison within groups
† P values indicate comparison between the changes of each variable between two groups
‡ According to ultrasound exam

Our results showed reduction in serum ALT, and hepatic steatosis in the Cit group; however there was no significant difference between two groups. Results of two experimental studies have shown that Cit supplementation along with high-fat diet or 60% fructose diet can prevent the induction of raising hepatic steatosis in rat [11, 13]. This discrepancy might be due to low dosage of our supplements and/or short duration of the study.

Previous studies reported that Cit down regulated genes expression of Sterol regulatory element-binding transcription factor 1 (SREBF1) and carbohydrate-responsive element-binding protein (CHREBP), fatty acid synthesis (Fas) that decreased de novo lipogenesis (DNL). Cit reduced gene expression SREBF1 by affecting on mammalian target of rapamycin (mTOR) pathway and protein kinase B [13, 25, 26]. All these mechanism are involved in development of hepatic steatosis. Thus, another possibility for difference in our results with these studies is that prevention and reduction of hepatic steatosis may require different mechanisms. Though Cit supplementation was able to prevent fatty liver, its activity in treating fatty liver might be not as clear as that in prevention, particularly when administered at low dosages and short duration.

The important advantage of this study is that it is the first clinical trial that evaluated the effects of Cit on inflammation markers in human patients with NAFLD. Other strengths of this study is evaluating NF-κB activity in PBMC. Furthermore, participants were newly diagnosed patients with NAFLD; so, they did not receive any treatment before and during the study.

Conclusion
In conclusion, our results showed that 12 weeks supplementation with 2 g/day Cit improved inflammatory markers in patients with NAFLD. Further studies with longer period of supplementation and different dosages of Cit are needed to be able to conclude.

Limitations
One of the limitations of this study was that we did not use different dosages of Cit. We could not use higher dosages of Cit because we did not find enough evidence for their safety in human. Secondly, we could not obtain liver biopsy to estimate hepatic steatosis, and fibrosis. Liver biopsy is gold standard for the evaluation of liver fibrosis during of chronic liver diseases. However transient elastography (FibroScan®) used that provides quantitative, safely evaluation of NAFLD by scaling hepatic steatosis (CAP score) and fibrosis. This technique was a reliable, noninvasive way for identification of patients with significant hepatic steatosis and fibrosis. It is readily, replicability and its score has low inter- and intra-observer variability [27, 28]. Thirdly, the clinical significance of reduced inflammatory markers is not clear so additional studies are needed to see if these reductions translate to less liver- or cardiovascular-related endpoints.

Abbreviations
Cit: citrulline; NAFLD: non-alcoholic fatty liver disease; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: γ-glutamyl transferase; IR: insulin resistance; NASH: non-alcoholic steatohepatitis; TNF: tumor necrosis factor; NF-κB: nuclear factor kappa B; hs-CRP: high sensitive C reactive protein; BMI: body mass index; SREBF1: sterol regulatory element-binding transcription factor 1; mTOR: mammalian target of rapamycin; Fas: fatty acid synthesis; DNL: de novo lipogenesis; CHREBP: carbohydrate-responsive element-binding protein.

Authors’ contributions
ZD and AH prepared the proposal, obtained ethical approvals, applied for funding, provided data collection and wrote the manuscript. AH conceived the idea, provided the fund, and supervised the study. SA served as expert in NAFLD and contributed to the patients recruitment. ZY, MD, MH, and AF were involved in study analysis and paraclinical exams. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank all participants without whom this study was impossible.
References

1. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
2. Mohrati Z, Gibson DL, Hekmatdoost A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 2017;8(2):240–52.
3. Hillenbrand A, et al. Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors. BMC Res Notes. 2015;8:290.
4. Rayyan YM, Tayyem RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes Metab Syndr. 2018;12(4):569–75.
5. Ghaemi A, et al. How much weight loss is effective on nonalcoholic fatty liver disease? Hepatitis Monthly. 2013;13(12)e15227.
6. Yari Z, et al. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Int J Food Sci Nutr. 2016;67(4):461–9.
7. Emanat H, et al. The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. J Diabetes Metab Disord. 2015;14(2):103–14.
8. Eslamparast T, et al. Recent advances in dietary supplementation, in treatment of non-alcoholic fatty liver disease. World J Hepatol. 2015;7(2):204–12.
9. Eslamparast T, et al. Symbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535–42.
10. Hekmatdoost A, et al. Adherence to the dietary approaches to stop hypertension (DASH) and risk of nonalcoholic fatty liver disease. Int J Food Sci Nutr. 2016;67(8):1024–9.
11. Jegatheesan P, et al. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats. Br J Nutr. 2016;116(2):191–203.
12. Jegatheesan P, et al. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clin Nutr. 2016;35(1):175–82.
13. Jegatheesan P, et al. Citruline and nonessential amino acids prevent fructose-induced nonalcoholic fatty liver disease in rats. J Nutr. 2015;145(10):2273–9.
14. El-Kirsh AAA, Abd El-Wahab HMF, Abd-Ellah Sayed HF. The effect of L-arginine or L-citruline supplementation on biochemical parameters and the vascular aortic wall in high-fat and high-cholesterol-fed rats. Cell Biochem Function. 2011;29(5):414–28.
15. Joffin N, et al. Citruline counteracts overweight and aging-related effects on adiponectin and leptin expression in rat white adipose tissue. Biochem Open. 2015;1:1–5.
16. Breuilard C, et al. In vitro anti-inflammatory effects of citruline on peritoneal macrophages in Zucker diabetic fatty rats. Br J Nutr. 2015;113(1):120–4.
17. Saltzman ET, et al. Intestinal microbiome shifts, dysbiosis, inflammation and non-alcoholic fatty liver disease. Front Microbiol. 2018;9:61.
18. Health, N. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health; National Heart, Lung, and Blood Institute, September 1998. Publication No. 98-4083. 2006.
19. Ainsworth BE, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9):5498–504.
20. Ghaeffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods. Tehran Nashre Olume Keshavarzy. 1999:7-213.
21. Cai B, et al. Does citrulline have protective effects on liver injury in septic rats? BioMed Res Int. 2016;2016:1–8.
22. Perinotte-Olson C, et al. Nanoformulated copper/zinc superoxide dismutase reduces adipose inflammation in obesity. Obesity. 2016;24(1):148–56.
23. Sellmann C, et al. Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD). Eur J Nutr. 2017;56(8):2519–27.
24. Locatelli I, et al. NF-kB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses. Clin Sci. 2013;124(4):279–87.
25. Cuthbertson D. Citrulline: a new major signaling molecule or just another maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

Page 5 of 5